Explanipedia

Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2023

Aberrant activity of the H3K27 modifiers EZH2 and BRD4 is an important oncogenic driver for atypical teratoid/rhabdoid tumor (AT/RT), and each is potentially a possible therapeutic target for treating AT/RT. We, therefore, determined wheth…

Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2023

Aberrant activity of the H3K27 modifiers EZH2 and BRD4 is an important oncogenic driver for atypical teratoid/rhabdoid tumor (AT/RT), and each is potentially a possible therapeutic target for treating AT/RT. We, therefore, determined wheth…

Supplementary Figure from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2023

Supplementary Figure from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors

Supplementary Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2023

Supplementary Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors

Supplementary Figure from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2023

Supplementary Figure from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors

Supplementary Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2023

Supplementary Data from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors

Figure S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Figure S2

Data from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Purpose:Radiotherapy (RT) has long been and remains the only treatment option for diffuse intrinsic pontine glioma (DIPG). However, all patients show evidence of disease progression within months of completing RT. No further clinical benef…

Supplementary Data from Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma Open

Michael I. Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Μαρκέλλα Ζαννίκου, Liliana Ilut , et al. · 2023

Methods, Figures, legends and Tables

Figure S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Figure S2

Table S1 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Table S1

Table S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Table S2

Data from Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma Open

Michael I. Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Μαρκέλλα Ζαννίκου, Liliana Ilut , et al. · 2023

Purpose:Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiotherapy is the standard-of-care treatment for DIPG, but offers only transient relief of symptoms for patients with DIPG without providin…

Supplementary Data from Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma Open

Michael I. Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Μαρκέλλα Ζαννίκου, Liliana Ilut , et al. · 2023

Methods, Figures, legends and Tables

Data from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Purpose:Radiotherapy (RT) has long been and remains the only treatment option for diffuse intrinsic pontine glioma (DIPG). However, all patients show evidence of disease progression within months of completing RT. No further clinical benef…

Figure S1 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Figure S1

Figure S3 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Figure S3

Data from Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma Open

Michael I. Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Μαρκέλλα Ζαννίκου, Liliana Ilut , et al. · 2023

Purpose:Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiotherapy is the standard-of-care treatment for DIPG, but offers only transient relief of symptoms for patients with DIPG without providin…

Table S1 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Table S1

Figure S1 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Figure S1

Figure S3 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Figure S3

Table S2 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma Open

Hiroaki Katagi, Nundia Louis, Dusten Unruh, Takahiro Sasaki, Xingyao He , et al. · 2023

Supplementary Table S2

Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors Open

Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti , et al. · 2022

Aberrant activity of the H3K27 modifiers EZH2 and BRD4 is an important oncogenic driver for atypical teratoid/rhabdoid tumor (AT/RT), and each is potentially a possible therapeutic target for treating AT/RT. We, therefore, determined wheth…

Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma Open

Hiroaki Katagi, Nozomu Takata, Yuki Aoi, Yongzhan Zhang, Emily J. Rendleman , et al. · 2021

Background Diffuse intrinsic pontine glioma (DIPG) is associated with transcriptional dysregulation driven by H3K27 mutation. The super elongation complex (SEC) is required for transcriptional elongation through release of RNA polymerase I…

Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma Open

Michael I. Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Μαρκέλλα Ζαννίκου, Liliana Ilut , et al. · 2020

Purpose: Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiotherapy is the standard-of-care treatment for DIPG, but offers only transient relief of symptoms for patients with DIPG without providi…

DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG Open

Ilango Balakrishnan, Etienne Danis, Angela Pierce, Krishna Madhavan, Dong Wang , et al. · 2020

BACKGROUND Diffuse intrinsic pontine gliomas (DIPGs) driven by mutations in the histone 3 (H3) gene (H3K27M) are aggressive pediatric brain tumors for which there is no curative therapy. METHODS To identify novel therapeutic targets we per…

DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA Open

Takahiro Sasaki, Hiroaki Katagi, Stewart Goldman, Oren J. Becher, Rintaro Hashizume · 2020

BACKGROUND Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brain tumor and the majority of patients die within 2 years after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include the infi…

DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA Open

Hiroaki Katagi, Nozomu Takata, Yuki Aoi, Yongzhan Zhang, Emily J. Rendleman , et al. · 2020

Diffuse intrinsic pontine glioma (DIPG) is highly aggressive brain stem tumor and needed to develop novel therapeutic agents for the treatment. The super elongation complex (SEC) is essential for transcription elongation through release of…

ET-03 Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse midline glioma Open

Takahiro Sasaki, Hiroaki Katagi, Becker Oren, Goldman Stewart, Naoyuki Nakao , et al. · 2020

Background: Diffuse midline glioma (DMG) is a fatal childhood brain tumor and the majority of patients die within 2 years after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include the infiltrative n…

Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG Open

Ilango Balakrishnan, Etienne Danis, Angela Pierce, Krishna Madhavan, Dong Wang , et al. · 2020

Hiroaki Katagi YOU? Author Swipe